Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...345678910111213...3132»
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Retrospective data, Journal:  Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. (Pubmed Central) -  Dec 28, 2021   
    We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm...Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide.
  • ||||||||||  Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, Adverse events:  Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. (Pubmed Central) -  Dec 22, 2021   
    The most common side effects of the Sputnik-V, AZD-1222, and Covaxin vaccine among Birjand (Iran) healthcare workers were injection site pain, muscle pain, fatigue, fever, and headache. Age and gender were the most important variables in the prevalence of vaccine side effects.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Clinical, Journal:  Seroprevalence of anti S1 SARS-CoV-2 antibodies in workers vaccinated with Sputnik V at a public hospital in Buenos Aires (Pubmed Central) -  Dec 18, 2021   
    In a subgroup of 21 participants with high titers of anti-S1 IgG antibodies and with no apparent previous COVID-19, 11 individuals were positive for antibodies against the SARS-CoV-2 nucleocapsid. It is concluded that most of the vaccinated health workers developed antibodies and that those who had the disease prior to vaccination had higher antibody titers than those who did not have the disease.
  • ||||||||||  Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Retrospective data, Review, Journal:  Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. (Pubmed Central) -  Dec 16, 2021   
    While each of nine vaccines was tested in the unique clinical trial as compared to control, based on indirect comparison, BNT162b2 and mRNA-1273 vaccines were ranked with the highest probability of efficacy against symptomatic COVID-19 (P-scores 0.952 and 0.843, respectively), followed by Gam-COVID-Vac (P-score 0.782), NVX-CoV23730 (P-score 0.700), CoronaVac (P-score 0.570), BN02 (P-score 0.428), WIV04 (P-score 0.327), and Ad26.COV2.S (P-score 0.198)...In our indirect comparison, the BNT162b2 and mRNA-1273 vaccines, which use mRNA technology, were associated with the highest efficacy to prevent symptomatic COVID-19 compared to other vaccines. This finding may have importance when deciding which vaccine to use, together with other important factors as availability of the vaccines, costs, logistics, side effects, and patient acceptability.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute, Spikevax (elasomeran) / Moderna, Takeda
    Clinical, Review, Journal:  Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. (Pubmed Central) -  Dec 16, 2021   
    Since SARS-CoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world's population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Review, Journal:  Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview. (Pubmed Central) -  Dec 1, 2021   
    SARS-CoV-2 vaccines in general may cause thromboembolic events, such as cerebral vein thrombosis, and mRNA-based vaccines in particular may cause myocarditis/pericarditis, with the latter more likely to occur in younger adults after the second vaccination dose. Nevertheless, the advantages of these vaccines for ending the pandemic and/or decreasing the mortality rate outweigh any risk for the rare cardiovascular complications.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Clinical, Journal:  Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina. (Pubmed Central) -  Nov 30, 2021   
    Data presented herein provides essential knowledge regarding the kinetics of antibodies induced by SPUTNIK V up to six months after immunization, and suggests that when considering one-dose vaccination policies for individuals with previous SARS-CoV-2 infection, serological studies to determine basal titers may be important, independent of when diagnosis occurred. Tucumán Public Health System (SIPROSA), Argentinean National Research Council (CONICET), National University of Tucumán (UNT).
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute, Turkovac / Health Institutes of Turkey
    Journal:  Development of an Inactivated Vaccine against SARS CoV-2. (Pubmed Central) -  Nov 29, 2021   
    P3
    ERUCoV-VAC has been authorized by the Turkish Medicines and Medical Devices Agency and has now entered phase 3 clinical development (NCT04942405). The name of ERUCoV-VAC has been changed to TURKOVAC in the phase 3 clinical trial.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia () -  Nov 24, 2021 - Abstract #ASH2021ASH_6238;    
    Socio-demographic factors such as gender, education, marriage status appeared to be significant for this decision. Considering the frequent concerns of the possibility of vaccination with CML diagnosis as well as the fear of complications, hematologists should provide a relevant clarifying information on these issues.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, Adverse events:  Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. (Pubmed Central) -  Nov 12, 2021   
    Among a total of 238 participants, more than 90% after the first and second dose of vaccine had a detectable level of SARS-CoV-2 RBD antibody and SARS-CoV-2 neutralizing antibody. Although the overall rate of adverse effects was higher than the interim results from randomized controlled trials, our findings support the manufacturer's reports about the high humoral immunogenicity of vaccine against COVID-19.